A significantly higher 5-year survival rate was seen in a small subset of patients with NSCLC treated with nivolumab.
Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer RiskApril 19, 2017
Whole genome sequencing of more than 3000 survivors of childhood cancers demonstrates the value of genetic testing for potential second cancers in this population.
Continuing immunotherapy after disease progression extends survival for some patients with head and neck cancer.
The joint report states that overall cancer rates have decreased for men, women, and children in all major race and ethnic groups. However, progress has been limited for some cancers.
Checkpoint inhibitor pembrolizumab appears well-tolerated with antitumor activity in patients with malignant pleural mesothelioma.
A phase 3 analysis of SWOG Intergroup Trial S0033 reveals that imatinib significantly extends survival in patients with GIST.
Individuals with serious carcinoma of the ovary or peritoneum experienced improved progression-free survival after hormone maintenance therapy.
The addition of pravastatin to first-line chemotherapy did not improve overall survival or progression-free survival in patients with small-cell lung cancer.
Adjuvant trastuzumab following chemotherapy significantly improves long-term disease-free survival in women with HER2-positive early breast cancer, according to study data.
Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.
Investigators determined the impact of socioeconomic status on disease status at presentation and survival among patients with head and neck squamous cell carcinoma.
Use of Adjuvant gemcitabine plus capecitabine for patients with pancreatic cancer who have undergone tumor resection resulted in a modest increase short-term survival.
There are a growing number of NSCLC patients with advanced disease who are opting to forgo treatment despite the fact that receiving standard of care treatment leads to a higher OS.
The timing of surgery taking place following an endometrial cancer diagnosis may adversely impact survival.
Seluminitinib in combination with an AKT inhibitor did not improve survival compared with modified FOLFOX in previously treated metastatic pancreatic cancer.
Weak social ties are associated with poorer survival and a higher risk of breast cancer recurrence, researchers say.
A new meta-analysis examines the impact of palliative care services on patients' and caregivers' quality of life and outcomes.
CDK4/6 Inhibitor Plus Aromatase Inhibitor Improves Progression-Free Survival in Metastatic Breast CancerOctober 12, 2016
Adding ribociclib to letrozole significantly improves progression-free survival for postmenopausal women with metastatic hormone receptor (HR)-positive breast cancer, compared with hormone therapy alone.
Adding daratumumab to lenalidomide and dexamethasone significantly prolonged progression-free survival compared with lenalidomide plus dexamethasone alone in patients with relapsed or refractory multiple myeloma.
Patients with oropharyngeal tumors that harbor HPV16 have higher 5-year survival and lower recurrence rates than patients with tumors that harbor other HPV strains or are HPV-negative.
Continued adoption of stereotactic body radiation therapy (SBRT) to treat early stage NSCLC improved OS and lung cancer-specific survival, according to a study presented at the 2016 annual meeting of the American Society for Radiation Oncology.
The combination of adjuvant bevacizumab and capecitabine failed to improve disease-free survival compared with capecitabine alone in patients with mCRC who had undergone potentially curative surgery.
Hematopoietic stem cell transplantation (HCT) is found to increase expression of a genetic code used to make proteins, leading to a biological aging of immune cells equivalent to 30 years of chronological age.
[Journal of Gastrointestinal Oncology] This research examines factors associated with survival in patients with brain metastasis from esophageal cancer.
HIV is associated with reduced cancer-specific survival among women with invasive cervical cancer.
Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple MyelomaAugust 16, 2016
The addition of elotuzumab to bortezomib/dexamethasone appears to increase progression-free survival in relapsed/refractory multiple myeloma (RRMM).
Patients with metastatic non-small cell lung cancer demonstrated prolonged median progression-free survival with the administration of erlotinib below the maximum tolerated dose.
Research indicates that metformin can confer improved survival for patients with colorectal cancer that also have diabetes.
Treatment with daratumumab, lenalidomide, and dexamethasone (DRd) may be superior to lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma.
Dasatinib and nilotinib are associated with similar response rates and survival outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP).
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|